Biogen Inc BIIB:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:03 AM EST
289.31
+3.37 (+1.18%)
+3.37 (+1.18%)Volume
145,772
52 week range
187.16 - 311.88
- Open287.00
- Day High290.31
- Day Low286.77
- Prev Close285.94
- 52 Week High311.88
- 52 Week High Date11/30/22
- 52 Week Low187.16
- 52 Week Low Date05/09/22
Key Stats
- Market Cap41.661B
- Shares Out144.00M
- 10 Day Average Volume0.95M
- Dividend-
- Dividend Yield-
- Beta0.22
- YTD % Change4.65
KEY STATS
- Open287.00
- Day High290.31
- Day Low286.77
- Prev Close285.94
- 52 Week High311.88
- 52 Week High Date11/30/22
- 52 Week Low187.16
- 52 Week Low Date05/09/22
- Market Cap41.661B
- Shares Out144.00M
- 10 Day Average Volume0.95M
- Dividend-
- Dividend Yield-
- Beta0.22
- YTD % Change4.65
RATIOS/PROFITABILITY
- EPS (TTM)19.63
- P/E (TTM)14.74
- Fwd P/E (NTM)18.31
- EBITDA (TTM)3.398B
- ROE (TTM)24.69%
- Revenue (TTM)10.363B
- Gross Margin (TTM)77.15%
- Net Margin (TTM)22.88%
- Debt To Equity (MRQ)49.15%
EVENTS
- Earnings Date02/15/2023
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Latest On Biogen Inc
Content From Our Affiliates
Profile
MOREBiogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA...
Stelios Papadopoulos Ph.D.
Independent Chairman of the Board
Christopher Viehbacher
President, Chief Executive Officer, Director
Michael McDonnell
Chief Financial Officer, Executive Vice President
Susan Alexander Esq., J.D.
Executive Vice President, Chief Legal Officer and Secretary
Priya Singhal M.D.
Executive Vice President - Head of Development
Address
225 Binney Street
Cambridge, MA
02142
United States